?PROJECT3 Theextraordinaryanddurablepatientresponseobservedinrecentimmunotherapytrialshavecatapultedtherole of immunosuppressive checkpoints to the forefront of mechanisms of disease maintenance and treatment response. On the wake of this progress, there have been renewed efforts to map the cellular and signaling requirements of local immunosuppression with the goal to expand immunotherapy options to common malignancies,includingprostatecancer.Inthiscontext,anabnormaldifferentiationofmyeloidcellsisoneofthe major immunological hallmarks of cancer. This reflects the expansion of pathologically activated immature myeloid cells, Myeloid-Derived Suppressor Cells (MDSC) with the ability to suppress a variety of immune functionsintumors,andlimittheefficacyofimmunotherapy.Despitetheirimportanceintumormaintenance,and aspotentialdriversofmetastaticcompetency,therearestilllargegapsinourunderstandingofMDSCfunctions. Howthesecellsaccumulateinprimaryaswellasmetastaticsites,potentiallycontributingtoametastaticniche,is poorly understood, and their metabolic requirements have not been explored. In prostate cancer, the role of MDSC is unknown. The present application is designed to fill this knowledge gap and explore an innovative hypothesis for MDSC function. We propose that mitochondrial metabolic reprogramming critically regulates the immunosuppressive checkpoints maintained by MDSC in the prostate cancer microenvironment, ultimately contributingtodiseaseprogressionandincreasedmetastaticcompetency.Consistentwiththismodel,ourrecent results have shown that MDSC have more mitochondria than mature neutrophils or monocytes, and thus produce more ATP, which in turn supports increased cell motility and homing to primary or metastatic tumor sites. Biochemically, we have shown that this pathway involves deregulated production of reactive oxygen species (ROS) via upregulation of cytoplasmic NADPH oxidase, increased oxidation of proteins and phospholipids, and ultimately damage of the mitochondrial outer membrane resulting in organelle dysfunction andcelldeath.WealsosuggestthatmitochondrialdamageprogressivelyaccumulatesduringMDSCmigration fromthebonemarrow(whereitisminimal)totissues(whereitbecomesextensive).Inthefirstspecificaim,we will characterize the mechanism of increased MDSC migration in prostate cancer and test the role of mitochondrialmetabolicreprogrammingandcellularrespirationinthisresponse.Thesecondspecificaimwewill testtheconceptthatmitochondrialdamageinMDSCisaccumulatedwithaprecise,developmentallyregulated timing during migration of these cells from the bone marrow to peripheral tissues. The third specific aim will dissect the hypothesis that damaged mitochondria contribute to MDSC-mediated immunosuppression, and evaluate novel therapeutic strategy targeting mitochondria in MDSC. Synergistically with the other Projects on this P01 application, Project 3 is designed to elucidate novel mechanistic requirements of local immunosuppressionthatmaypromoteprostatecancerprogressiontoanincurable,metastaticstage.Theresults willuncovernovelvulnerabilitiesofMDSCsuitablefortherapeuticinterventioninpatientswithadvancedprostate cancer.

Public Health Relevance

?PROJECT3 Herewestudytheroleofoxidativemetabolisminthefunctionofmyeloid-derivedsuppressorcells(MDSC). MDSCareenrichedformitochondriaandproducelargeamountofATP,whichsupportenhancedcellmotility andactivemigrationifthesecells.ActivationofMDSCintissuesleadstomitochondriadamagethatcontribute toMDSCmediatedimmunesuppression.Thisinformationwillbeusedtodevelopnewmethodsoftargeting thesecells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA140043-07A1
Application #
9150027
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (M1))
Project Start
Project End
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
7
Fiscal Year
2016
Total Cost
$212,054
Indirect Cost
$79,742
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Patel, Sima; Fu, Shuyu; Mastio, Jerome et al. (2018) Unique pattern of neutrophil migration and function during tumor progression. Nat Immunol 19:1236-1247
Wang, Tao; Huang, Jiayi; Vue, Mai et al. (2018) ?v?3 Integrin Mediates Radioresistance of Prostate Cancer Cells Through Regulation of Survivin. Mol Cancer Res :
Seo, Jae Ho; Agarwal, Ekta; Bryant, Kelly G et al. (2018) Syntaphilin Ubiquitination Regulates Mitochondrial Dynamics and Tumor Cell Movements. Cancer Res 78:4215-4228
Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Ishida, Chiaki Tsuge; Shu, Chang; Halatsch, Marc-Eric et al. (2017) Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma. Oncotarget 8:37140-37153
Altieri, Dario C (2017) AML Therapy: Wake Up the Guardian and Cut Loose the Executioners. Cancer Cell 32:719-720
Karpel-Massler, Georg; Ishida, Chiaki Tsuge; Bianchetti, Elena et al. (2017) Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. Cancer Res 77:3513-3526
Caino, M Cecilia; Seo, Jae Ho; Wang, Yuan et al. (2017) Syntaphilin controls a mitochondrial rheostat for proliferation-motility decisions in cancer. J Clin Invest 127:3755-3769
Altieri, Dario C (2017) Mitochondria on the move: emerging paradigms of organelle trafficking in tumour plasticity and metastasis. Br J Cancer 117:301-305

Showing the most recent 10 out of 77 publications